pneumonia
frequent
infecti
complic
solid
organ
transplant
sot
occurr
pneumonia
advers
impact
graft
recipi
surviv
well
cost
care
sot
numer
caus
pneumonia
sot
recipi
etiolog
result
infect
other
caus
signific
morbid
mortal
result
vari
clinic
present
etiolog
pneumonia
sot
recipi
arriv
specif
microbiolog
diagnosi
challeng
import
optim
care
especi
complic
refractori
pneumonia
section
clinic
present
differenti
diagnosi
diagnost
test
empir
antimicrobi
treatment
pneumonia
sot
recipi
review
section
within
ast
id
guidelin
referenc
inform
regard
diagnosi
treatment
specif
pathogen
caus
pneumonia
vulner
popul
clinic
present
pneumonia
sot
recipi
highli
variabl
tradit
present
cough
increas
sputum
product
fever
alway
prompt
evalu
pneumonia
howev
frequent
subtl
symptom
predomin
diagnosi
pneumonia
reach
care
clinic
evalu
clinic
evolut
vari
rapid
indic
bacteri
viral
pathogen
subacut
chronic
present
often
seen
fungal
mycobacteri
infect
high
index
suspicion
pneumonia
essenti
sign
infect
present
solid
organ
transplant
recipi
lung
involv
evalu
transplant
patient
present
unexplain
fever
even
absenc
clinic
find
differenti
diagnosi
pneumonia
sot
recipi
includ
infecti
etiolog
tabl
understand
infecti
etiolog
patient
driven
epidemiolog
investig
otherwis
healthi
adult
pediatr
earlier
era
studi
pneumonia
sot
recipi
focus
high
incid
opportunist
infect
invas
mold
infect
cytomegaloviru
cmv
improv
infect
prevent
strategi
better
diagnost
tool
newer
immunosuppress
strategi
import
bacteri
viral
infect
pneumonia
increasingli
differenti
diagnosi
pneumonia
sot
recipi
depend
upon
multitud
factor
includ
limit
age
time
net
state
immunosuppress
specif
organ
transplant
environment
exposur
site
pneumonia
acquisit
commun
vs
radiograph
infiltr
pattern
risk
pneumonia
sot
recipi
determin
degreedepth
healthcar
andor
pneumonia
frequent
diagnos
earli
period
two
seri
earli
onset
pneumonia
transplant
domin
bacteri
etiolog
major
major
pneumonia
episod
occur
later
occur
year
renal
recipi
episod
occur
month
multicent
point
preval
type
organ
transplant
influenc
incid
time
microbiolog
spectrum
pneumonia
sot
lung
transplant
pose
uniqu
challeng
given
potenti
infect
recipi
airway
colon
impact
occurr
microbiolog
pneumonia
prospect
multicent
studi
pneumonia
lung
transplant
recipi
pneumonia
incid
episod
per
lung
transplant
per
though
bacteri
pneumonia
frequent
etiolog
fungal
viral
pneumonia
togeth
account
episod
major
pneumonia
episod
seri
occur
two
month
larg
cohort
sot
recipi
invas
fungal
infect
aspergillu
common
ifi
lung
transplant
recipi
presum
mani
invas
aspergillosi
ia
episod
present
primari
lung
studi
half
ia
episod
occur
year
retrospect
studi
adult
small
bowelmultiviscer
transplant
smbmv
recipi
recipi
develop
infect
involv
lung
period
due
pseudomona
prospect
studi
infect
smbmv
recipi
patient
develop
pneumonia
though
pneumonia
data
radiograph
featur
contribut
narrow
differenti
diagnosi
pneumonia
sot
recipi
though
frequent
lead
identif
specif
etiolog
diffus
bilater
infiltr
suggest
rang
etiolog
includ
cmv
respiratori
virus
mycoplasma
legionella
pneumocysti
jirovecii
pjp
ground
glass
mix
ground
glassmicronodular
infiltr
rais
concern
pjp
singl
multinodular
lung
involv
indic
potenti
invas
mold
infect
nocardia
tuberculosi
tb
mycobacteri
diseas
endem
fungal
infect
associ
lung
infiltr
mediastin
hilar
adenopathi
rais
concern
tb
endem
fungal
infect
presenc
pleural
effus
empyema
suggest
rang
etiolog
includ
bacteri
pneumonia
cryptococcu
fungal
infect
tuberculosi
depend
clinic
present
exposur
epidemiolog
environment
exposur
season
also
significantli
influenc
pneumonia
etiolog
geograph
locat
donor
recipi
may
impart
risk
endem
fungal
infect
histoplasma
coccidioid
blastomyc
penicillium
tb
burkholderia
zoonot
pneumonia
occur
secondari
array
pathogen
follow
exposur
bird
chlamydia
psittaci
catsdog
pasteurella
multocida
rabbit
wildlif
francisella
tularensi
hors
rhodococcu
equi
farm
anim
coxiella
burnetti
environment
exposur
contamin
water
legionella
pneumophila
pseudomona
aeruginosa
well
soil
cryptococcu
nocardia
penicillium
endem
fungi
mold
also
indic
potenti
etiolog
season
commun
contact
contribut
rel
risk
respiratori
viral
infect
influenza
parainfluenza
enterovirus
potenti
pathogen
caus
pneumonia
sot
recipi
includ
bacteria
virus
fungi
parasit
tabl
though
specif
etiolog
discuss
greater
detail
section
guidelin
seri
broad
categori
microbiolog
etiolog
caus
pneumonia
sot
recipi
merit
attent
bacteri
pneumonia
solid
organ
transplant
recipi
caus
organ
well
pathogen
set
lung
transplant
hospit
acquisit
includ
pneumonia
occur
predominantli
earli
pneumonia
becom
rel
frequent
later
bacteri
pneumonia
pathogen
includ
streptococcu
haemophilu
influenza
mycoplasma
spp
legionella
spp
chlamydia
spp
nosocomialopportunist
bacteri
etiolog
includ
pseudomona
spp
enter
bacilli
well
stenotrophomona
spp
other
addit
bacteria
nocardia
tubercul
mycobacteria
signific
pathogen
sot
fungal
pulmonari
infect
sot
recipi
due
pjp
aspergillu
spp
invas
mold
cryptococcu
endemicdimorph
fungi
histoplasma
blastomyc
though
prophylaxi
strategi
markedli
decreas
occurr
pjp
sot
recipi
infect
remain
problem
histoplasma
infect
sot
recipi
case
pulmonari
involv
infect
occur
first
year
cryptococc
infect
may
present
pneumonia
alon
dissemin
includ
central
nervou
system
sot
notabl
cmv
infect
predispos
invas
aspergillosi
sot
viral
etiolog
pneumonia
sot
recipi
includ
dna
virus
cmv
herpesvirus
well
respiratori
rna
virus
includ
parainfluenza
less
data
exist
frequenc
infect
rhinovirus
coronavirus
respiratori
enterovirus
caus
pneumonia
sot
addit
viral
respiratori
tract
infect
predispos
secondari
bacteri
lung
transplant
recipi
high
risk
lower
respiratori
tract
infect
due
respiratori
potenti
signific
increas
acut
reject
rate
declin
lung
parasit
infect
rare
caus
pneumonia
sot
recipi
toxoplasma
infect
reactiv
infrequ
report
caus
pneumon
either
part
dissemin
strongyloid
hyperinfect
syndrom
occur
result
anteced
recipi
infect
transmiss
present
bilater
multifoc
andor
interstiti
pulmonari
infiltr
without
bacteri
array
etiolog
mimic
infecti
pneumonia
sot
recipi
tabl
lymphoprolif
diseas
ptld
may
present
lungthorac
involv
includ
pulmonari
nodul
mediastin
adenopathi
especi
transplant
pulmonari
ptld
also
radiograph
mimic
infecti
etiolog
mtor
pneumon
infrequ
though
potenti
sever
medic
side
effect
gener
resolv
discontinu
mtor
inhibitor
therapi
may
infecti
etiolog
includ
pjp
respiratori
primari
metastat
lung
cancer
also
occur
sot
complic
pulmonari
embol
pulmonari
hemorrhag
pulmonari
edema
also
studi
prospect
compar
diagnost
approach
pneumonia
sot
recipi
specif
diagnost
test
evalu
systemat
individu
test
perform
often
defin
healthi
subject
group
subject
varieti
immunocompromis
condit
therefor
appropri
diagnost
evalu
pneumonia
sot
recipi
highli
individu
base
local
epidemiolog
local
avail
test
practic
paramet
well
risk
factor
exposur
medic
histori
guidelin
diagnosi
pneumonia
group
also
inform
though
alway
specif
appli
sot
tier
approach
diagnost
evalu
pneumonia
encompass
initi
approach
follow
extens
evalu
diagnosi
remain
unclear
patient
deterior
clinic
situat
critic
specif
diagnosi
initi
suspect
respect
test
appli
order
diagnost
test
modifi
one
potenti
diagnost
approach
pneumonia
sot
recipi
outlin
figur
diagnost
evalu
sot
recipi
suspect
confirm
pneumonia
perform
use
tier
approach
pace
extent
evalu
inform
sever
acuiti
present
degre
immunosuppress
patient
risk
factorexposur
histori
strong
low
recommend
use
current
pneumonia
sever
score
sot
recipi
pneumonia
strong
low
pneumonia
sever
score
evalu
patient
pneumonia
variabl
abil
stratifi
sever
clinic
studi
pneumonia
sever
score
system
perform
sot
recipi
though
psi
score
poor
perform
characterist
cancer
patient
present
practition
evalu
sot
recipi
symptom
sign
pneumonia
assess
follow
initi
evalu
featur
patient
medic
transplant
immun
social
histori
strong
moder
prior
microbi
colon
current
prior
antimicrobi
prophylaxi
regimen
strong
moder
histori
exposur
would
suggest
risk
untreat
latent
infect
latent
tb
infect
coccidioidomycosi
strongyloidiasi
strong
moder
acuiti
patient
clinic
present
use
inform
guid
differenti
diagnosi
diagnost
evalu
empir
antimicrobi
therapi
strong
low
need
contact
respiratori
isol
assess
act
upon
earli
patient
evalu
avoid
exposur
sot
recipi
patient
andor
staff
potenti
contagi
pathogen
strong
high
local
epidemiolog
respiratori
virus
particular
influenza
viru
review
consid
evalu
strong
high
initi
evalu
sot
recipi
pneumonia
includ
blood
radiolog
test
consider
given
viral
detect
nasopharynx
clinician
obtain
complet
blood
count
differenti
electrolyt
chemistri
liver
function
test
part
initi
laboratori
evalu
aid
diagnosi
determin
risk
toxic
associ
empir
direct
antimicrobi
treatment
strong
low
blood
cultur
obtain
present
pneumonia
prior
initi
antibiot
therapi
especi
patient
febril
requir
hospit
strong
low
blood
cultur
yield
etiolog
organ
low
healthi
sot
recipi
pneumonia
posit
blood
cultur
significantli
impact
clinic
chest
perform
sot
patient
suspect
pneumonia
strong
moder
perform
chest
ct
scan
initi
evalu
pneumonia
recommend
set
high
acuiti
high
net
state
immunosuppress
weak
low
risk
ill
attribut
cmv
assess
consid
cmv
serostatu
statu
prophylaxi
durat
time
depth
immunosuppress
sot
patient
present
symptom
indic
pneumonia
strong
low
test
urin
legionella
antigen
recommend
weak
low
low
though
sensit
low
urin
test
detect
pneumophila
speci
diagnosi
legionella
test
acceler
diagnosi
institut
appropri
antimicrobi
test
nasopharynx
influenza
viru
pcr
season
appropri
time
recommend
clarifi
need
antivir
treatment
strong
high
multiplex
molecular
respiratori
viru
test
recommend
evalu
pneumonia
sot
recipi
season
high
respiratori
viru
incid
weak
moder
identifi
respiratori
viral
etiolog
impact
clinic
decis
regard
evalu
well
need
antimicrobi
therapi
though
impact
specif
evalu
sot
older
children
adult
sputum
product
present
sputum
cultur
recommend
gram
stain
bacteri
cultur
weak
low
contribut
inflammatori
marker
leukocyt
count
protein
procalcitonin
extens
studi
tool
gener
practition
decid
whether
empir
antibiot
treatment
may
necessari
mix
sever
studi
evalu
util
procalcitonin
measur
detect
differenti
bacteri
infect
solid
organ
transplant
review
importantli
procalcitonin
level
impact
surgeri
well
atg
administr
may
decreas
util
assay
first
week
gener
though
studi
evalu
procalcitonin
use
set
sot
recipi
pneumonia
elev
procalcitonin
level
may
indic
presenc
infect
elev
procalcitonin
level
beyond
first
week
may
indic
presenc
bacteri
infect
howev
data
limit
sot
recipi
specif
clinic
scenario
appli
procalcitonin
test
clear
pneumonia
establish
imag
select
laboratori
evalu
underway
empir
therapi
discuss
start
see
empir
initi
treatment
section
clinician
progress
second
tier
evalu
figur
despit
empir
therapi
clinic
situat
improv
first
hour
deterior
diagnosi
made
follow
first
tier
diagnost
evalu
figur
second
tier
test
perform
focu
four
select
test
first
tier
appropri
imag
studi
defin
locat
natur
pulmonari
involv
expand
diagnost
evalu
guid
exposur
radiograph
result
clinic
cours
invas
test
goal
secur
microbiolog
diagnosi
target
treatment
figur
laboratori
test
obtain
part
initi
evalu
perform
weak
low
done
yet
ct
scan
chest
perform
better
delin
radiolog
pattern
locat
infiltr
ident
potenti
opportun
invas
diagnost
procedur
strong
high
addit
blood
test
guid
radiograph
pattern
exposur
degre
immunosuppress
includ
antigen
andor
serolog
evalu
endem
mycos
strong
high
see
endem
fungi
section
edit
ast
id
guidelin
fungal
biomark
measur
bloodserum
galactomannan
poor
perform
characterist
sot
recipi
compar
hsct
studi
evalu
whether
perform
characterist
vari
depend
time
infect
given
pauciti
data
evalu
util
recommend
use
test
current
sot
recipi
strong
low
see
aspergillu
candida
pneumocysti
section
edit
ast
id
guidelin
case
invas
test
need
obtain
diagnosi
invas
procedur
diagnost
test
sot
recipi
pneumonia
includ
bronchoscopi
bronchoalveolar
lavag
bal
transbronchi
biopsi
biopsi
thoracotomi
vat
lung
biopsi
open
lung
biopsi
procedur
particularli
import
diagnosi
fungal
diseas
see
aspergillu
cryptococcu
endem
fungi
emerg
fungi
section
edit
ast
id
guidelin
evalu
caus
malign
though
potenti
exist
achiev
diagnosi
one
method
decis
pursu
procedur
evalu
sot
recipi
pneumonia
must
balanc
procedur
risk
potenti
benefit
physician
care
sot
recipi
pneumonia
low
threshold
procedur
evalu
especi
set
patient
improv
highli
immunocompromis
diagnosi
remain
uncertain
strong
moder
bronchoalveolar
lavag
offer
opportun
obtain
microbiolog
diagnosi
either
without
transbronchi
biopsi
util
bal
sot
recipi
pneumonia
lung
infiltr
lung
nodul
evalu
sever
small
microbiolog
yield
bal
studi
rang
highest
yield
patient
nosocomi
onset
symptom
month
importantli
microbiolog
yield
clearli
influenc
probabl
infect
rel
incid
infect
distinct
bal
studi
list
figur
propos
complet
list
diagnost
option
extens
perform
complet
list
studi
may
need
sot
recipi
pneumonia
recommend
perform
bal
set
diffus
focal
pulmonari
infiltr
patient
failur
improv
empir
antibacteri
therapi
diagnosi
reach
test
strong
moder
decis
proceed
bal
versu
lung
biopsi
initi
invas
test
must
highli
individu
patient
depend
clinician
riskbenefit
analysisw
recommend
follow
studi
complet
bal
fluid
evalu
modif
need
depend
individu
patient
clinic
present
radiograph
find
clinic
cours
figur
bacteri
fungal
viral
mycobacteri
cultur
see
aspergillu
cryptococcu
endem
fungi
emerg
fungi
cmv
hsv
vzv
respiratori
virus
mycobacteri
tuberculosi
nocardia
section
edit
ast
id
guidelin
strong
moder
test
includ
stain
nucleic
test
pjp
bal
fluid
strong
high
particular
patient
either
longer
receiv
prophylaxi
prophylaxi
see
pneumocysti
section
edit
ast
id
guidelin
stain
patient
radiograph
find
suggest
invas
fungal
infect
strong
low
patient
radiograph
find
suggest
invas
fungal
infect
weak
low
test
endem
fungal
infect
histoplasma
blastomyc
coccidioid
paracoccidioid
patient
compat
clinic
histori
geograph
exposur
risk
strong
low
test
pcr
qnat
film
array
test
follow
pathogen
depend
test
avail
patient
clinic
histori
exposur
risk
radiograph
find
strong
low
mycoplasma
spp
ureaplasma
spp
andor
legionella
nocardia
mold
mycobacterium
tuberculosi
evalu
offer
abil
directli
identifi
infecti
agent
tissu
also
determin
histolog
pattern
inflamm
present
open
lung
biopsi
olb
studi
kidney
transplant
popul
bilater
lung
overal
olb
diagnost
yield
find
olb
result
therapeut
manag
chang
complic
frequent
olb
associ
higher
mortal
similar
studi
compar
sot
patient
diffus
lung
diseas
demonstr
therapeut
manag
chang
frequenc
percutan
lung
biopsi
evalu
one
seri
sot
recipi
parenchym
lung
nodul
diagnost
yield
seri
biopsi
frequent
diagnos
fungal
diseas
malign
yield
highest
use
aspir
core
biopsi
combin
procedur
complic
occur
decis
proceed
lung
biopsi
must
highli
individu
patient
depend
clinician
riskbenefit
analysi
recommend
lung
biopsi
open
vat
set
diffus
focal
pulmonari
infiltr
patient
failur
improv
empir
antibacteri
therapi
diagnosi
reach
test
bal
strong
moder
recommend
lung
biopsi
transbronchi
open
vat
patient
focal
pulmonari
nodul
diagnosi
alreadi
establish
mean
due
risk
malign
includ
ptld
invas
fungal
infect
weak
low
consider
given
close
serial
imag
prior
perform
invas
diagnost
procedur
case
risk
malign
andor
invas
fungal
infect
felt
low
weak
low
patient
live
geograph
area
impart
risk
endem
fungal
infect
exposur
histori
suggest
moder
high
risk
endem
fungal
infect
recommend
deferr
lung
biopsi
antigenserolog
assess
endem
fungal
infect
complet
weak
low
test
bacteri
pcr
base
panfung
mycobacteri
genu
pcr
univers
avail
system
studi
sot
recipi
howev
assay
may
help
patient
test
identifi
etiolog
unbias
sequenc
may
assist
defin
specif
etiolog
avail
though
clinic
studi
need
defin
util
diagnost
approach
pneumonia
given
complex
vari
natur
specif
treatment
individu
pathogen
caus
pneumonia
sot
recipi
section
address
recommend
empir
antimicrobi
therapi
set
variou
factor
significantli
impact
empir
antimicrobi
regimen
pneumonia
sot
recipi
degre
immunosuppress
pace
ill
onset
acut
subacut
chronic
signific
determin
breadth
empir
antimicrobi
therapi
provid
individu
patient
except
influenza
season
empir
therapi
may
includ
agent
direct
influenza
antibacteri
therapi
cornerston
initi
empir
therapi
pneumonia
sot
empir
antifung
chemotherapi
rare
initi
earli
except
instanc
clinic
radiolog
present
strongli
suggest
fungal
origin
choic
initi
therapi
depend
follow
consider
empir
treatment
regimen
pneumonia
sot
recipi
take
account
individu
patient
known
microbi
colon
well
prior
antimicrobi
resist
pattern
specif
colon
pathogen
organ
special
emphasi
resist
bacteria
colon
airway
lung
transplant
recipi
strong
low
influenza
season
empir
administr
antivir
drug
activ
influenza
recommend
sot
recipi
ill
includ
pneumonia
await
result
test
unless
access
detect
method
rapid
turnaround
time
strong
moder
see
rna
respiratori
virus
section
edit
ast
id
guidelin
stabl
patient
consid
suitabl
outpati
therapi
lower
risk
opportunist
infect
specif
pathogen
suspect
empir
therapi
cover
pneumonia
follow
nationalintern
guidelin
influenc
local
resist
preval
pattern
strong
low
fluoroquinolon
fq
coverag
respiratori
pathogen
may
consid
empir
therapi
set
strong
low
practition
consid
role
drug
interact
advers
reaction
increas
antimicrobi
resist
consid
risk
benefit
fq
use
sot
recipientsconsider
given
empir
coverag
intracellular
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
spp
sot
recipi
pneumonia
weak
low
greater
consider
given
empir
intracellular
pathogen
treatment
pediatr
sot
recipi
pneumonia
strong
moder
one
import
consider
select
use
empir
therapi
set
interact
present
macrolid
immunosuppress
agent
respiratori
fluoroquinolon
may
consid
set
high
incid
macrolid
resist
mycoplasma
spp
consider
given
issu
consid
risk
benefit
fq
use
weak
low
outpati
regimen
discuss
inclus
antibiot
therapi
staphylococcu
aureu
mrsa
pseudomona
spp
depend
local
resist
pattern
preval
individu
patient
infect
bacteri
colon
histori
well
featur
present
ill
eg
radiograph
evid
lung
abscess
strong
low
see
mrsa
mdr
gnr
section
edit
ast
id
guidelin
sot
recipi
requir
hospit
pneumonia
combin
therapi
agent
activ
agent
activ
intracellular
organ
mycoplasma
spp
children
legionella
spp
adult
recommend
strong
low
breadth
coverag
agent
use
depend
local
resist
pattern
especi
pneumonia
whether
nosocomi
approach
warrant
cover
pathogen
eg
recent
hospit
underli
chronic
bronchiectat
lung
diseas
presenc
prosthet
materi
fluoroquinolon
altern
set
strong
low
hospit
patient
nosocomi
pneumonia
internationaln
guidelin
appli
attent
local
guidelin
preval
epidemiolog
strong
moder
empir
therapi
must
adapt
new
clinic
microbiolog
find
appropri
initi
empir
therapi
measur
larg
part
patient
clinic
respons
close
monitor
includ
repeat
clinic
evalu
prerequisit
outpati
approach
feasibl
doubt
prevail
inpati
manag
favor
furthermor
empir
therapi
pneumonia
key
gap
antimicrobi
coverag
must
kept
mind
empir
regimen
optim
treat
nocardia
spp
pneumocysti
jirovecii
mycobacteri
infect
may
partial
mitig
activ
drug
use
empir
pneumonia
therapi
eg
imipenem
quinolon
oxazolidinon
addit
empir
antibacteri
regimen
clearli
provid
coverag
invas
opportunist
andor
endem
fungal
infect
clinician
care
sot
recipi
subacut
chronic
ill
present
includ
pneumonia
consid
pathogen
nocardia
tuberculosi
mycobacteria
endem
fungi
invas
mold
pathogen
requir
bronchoalveolar
fluid
tissu
test
diagnosi
treatment
entail
prolong
cours
antimicrobi
regimen
empir
therapi
usual
institut
prior
diagnost
test
procedur
howev
uniqu
situat
high
acuiti
inabl
perform
diagnost
procedur
empir
therapi
pathogen
may
need
diagnosi
treatment
pneumonia
sot
recipi
challeng
due
vari
clinic
present
numer
potenti
etiolog
breadth
empir
target
treatment
option
diagnost
strategi
must
consid
numer
factor
includ
time
degre
immunosuppress
environmentalcommunityhospit
exposur
season
epidemiolog
empir
treatment
larg
part
determin
local
epidemiolog
resist
pattern
novel
diagnost
techniqu
futur
prospect
studi
continu
impact
diagnosi
treatment
pneumonia
sot
recipi
author
declar
conflict
interest
